Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 121Neoplasms, Plasma Cell 36Neoplasms 14Carcinoma, Hepatocellular 13Recurrence 12Brain Neoplasms 12Prostatic Neoplasms 11Melanoma 11Central Nervous System Neoplasms 11Glioblastoma 10Leukemia 9Carcinoma, Non-Small-Cell Lung 9Leukemia, Lymphocytic, Chronic, B-Cell 8Gliosarcoma 8Waldenstrom Macroglobulinemia 7Sarcoma 7Lung Neoplasms 7Glioma 7Colorectal Neoplasms 7Carcinoma, Renal Cell 7Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Lymphoma, Mantle-Cell 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma 5Liver Neoplasms 5Kidney Neoplasms 5Immunoglobulin Light-chain Amyloidosis 5Myelodysplastic-Myeloproliferative Diseases 4Lymphoma, Follicular 4

Interventions

venetoclax 1saponin QA-21V1 1perflutren 1peginesatide 1hematide 1finerenone 1empagliflozin 1Thalidomide 1Stem Cell Transplantation 1Standard of Care 1Specimen Handling 1Simethicone 1Rocuronium 1Resistance Training 1Quillaja Saponins 1Protein Subunit Vaccines 1Practice Guidelines as Topic 1Kidney Transplantation 1Hypothermia, Induced 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Eplerenone 1Endurance Training 1Dexamethasone 1DM199 1Citric Acid 1Cholecalciferol 1Breathing Exercises 1Bortezomib 1Blood Specimen Collection 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Renal Insufficiency, Chronic × Thalidomide × Clear all
NCT02424851 2022-01-27

OPTIMAL

Oxford University Hospitals NHS Trust

Phase 2 Completed
31 enrolled 13 charts
Plasma cell

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡